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ABSTRACT 
Objective: The purpose of present study aims to design novel drug delivery system containing oxiconazole nitrate microsponges and to prepare 
microsponge gel. Oxiconazole nitrate is an antifungal drug used in the treatment of fungal infection having a poor aqueous solubility, side effects and 
adverse reactions. The microsponge delivery system is unique technology for controlled release of active agents.  
Methods: The microsponges were prepared by quasi-emulsion solvent diffusion method by using polymer eudragit S-100 and eudragit L-100. All 
the formulated microsponges were subjected for various evaluation parameters such as production yield, encapsulation efficiency, particle size 
analysis and in vitro drug release study. The optimised microsponge formulation F3 and F9 were further formulated as gel formulation for topical 
delivery. Prepared gel was evaluated for physical parameters like pH, spreadability, viscosity, drug content and in vitro diffusion study and 
compared with the marketed formulation.  
Results: The Fourier transform infrared radiation measurement (FTIR) and Differential scanning colorimetry (DSC) of drug and excipient confirm 
compatibility. Results revealed that quasi-emulsion solvent diffusion method is a suitable technique for the preparation of microsponges as most of 
the formulations were discrete and spherical in shape with a good production yield of 61.44% to 80.45% and The highest drug release for F3 and F9 
formulation was found to be 87.77 % and 83.24 % respectively for the 8 h. The microsponge gel formulation MGI (F3) showed the controlled release 
of oxiconazole nitrate for 12 h. The drug release data of optimised batch MGI (F3) were fitted into different kinetic models and showed that the drug 
release from gel formulation follows zero order release.  
Conclusion: As compared to conventional formulation, the prepared microsponge gel are expected to remain on the skin for a longer time, 
gradually releasing their contents over the time. Hence, oxiconazole nitrate microsponges and microsponge gel prepared in this study are promising 
as being more useful than conventional formulation therapy. 
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The novel drug delivery systems have been increasingly investigated 
to achieve targeted and controlled release of drugs as many of 
conventional delivery systems require high concentrations of active 
agents to be incorporated for effective therapy because of their low 
efficiency as delivery systems. Microsponges are highly cross-linked, 
patented, porous, polymeric microspheres that acquire the flexibility 
to entrap a wide variety of active ingredients that are mostly used 
for prolonged topical administration and recently for oral 
administration. Microsponges are designed to deliver a 
pharmaceutically active ingredient efficiently at minimum dose and 
also to enhance stability, elegance, flexibility in formulation, reduce 
side effects and modify drug release profile [1-3]. 
The microsponge system can prevent excessive accumulation of 
ingredients within the epidermis and the dermis. These products are 
typically presented to the consumer in conventional forms like creams, 
gels or lotions and they contain relatively high concentration of active 
ingredients. Microsponges are polymeric delivery systems consisting 
of porous microspheres that can entrap a wide range of active 
ingredients such as emollients, fragrances, essential oils, sunscreens, 
and anti-infective, anti-fungal, and anti-inflammatory agents [4]. 
There have been concerns related to the conventional topical dosage 
forms such as lotions, creams, ointments and powder in terms of 
drug diffusion or release from the vehicle and delivery through the 
skin. Creams and lotions often provide poor bioavailability of the 
drug because they are rapidly cleared from the skin and poorly 
release the drug from the base. Non-hydrophilic ointments are 
oleaginous, greasy and are non-convenient to patients and also 
medicated powders for the topical application have short residence 
time on the skin. Gels are semisolid systems in which the movement 
of the dispersion medium is restricted by interlacing three-
dimensional network of particles or solvated macromolecules of 
dispersed phase. The increased viscosity caused by interlacing and 
consequently internal friction is responsible for the semisolid state. 
Also, a gel may consist of twisted matted strands often tied together 
by stronger types of Vander Waals Forces to form crystalline and 
amorphous regions throughout the system. The use of gel as a 
delivery system can increase the residence time of drugs on the skin 
and consequently enhance bioavailability. Gel delivery systems have 
several advantages such as the ease of administration, non-greasy, 
patient compliance, high residence time on the skin and better drug 
release [5]. Oxiconazole inhibits ergosterol biosynthesis, which is 
required for cytoplasmic membrane integrity of fungi. It acts to 
destabilize the fungal cytochrome P450 51 enzyme (also known as 
Lanosterol 14-alpha demethylase) [6]. This is vital in the cell 
membrane structure of the fungus. Its inhibition leads to cell lysis. 
Oxiconazole has also been shown inhibition of DNA synthesis and 
suppresses intracellular concentrations of ATP. Like other imidazole 
antifungals, Oxiconazole can increase membrane permeability to 
zinc, augmenting its cytotoxicity. 
Oxiconazole nitrate is a potent anti-fungal drug, used in the 
treatment of fungal infection. Oxiconazole is a cream or lotion 
applied to the skin in the treatment of tinea corporis, tinea pedis and 
tinea cruris. Oxiconazole nitrate is BCS-II drug. It has adverse effects 
include: Burning, itching, blistering, crusting, dryness or flaking of 
the skin, scaling, severe redness, soreness, swelling and pain in hairy 
areas with pus at the root of hair and side effects like pruritus, 
burning, irritation, erythema, stinging and allergic contact dermatitis 
and folliculitis, fissuring, maceration rash and nodules. 
Thus, alternative routes of administration for these drugs with novel 
drug delivery are being currently investigated. Oxiconazole nitrate 
microsponge gel have shown significant drug level in deep tissues 
such as fascia, muscle and synovium after topical application, which 
is a desirable feature for the relief of local symptoms with low dose, 
thereby reducing side effects.  
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In the present study, the oxiconazole microsponges were prepared 
using polymers such as eudragit S-100 and eudragit L-100 at 
different proportions using an individual polymer with the help of 
quasi-emulsion solvent diffusion method. The microsponge gel 
formulations were prepared from optimised oxiconazole nitrate 
microsponges using carbapol 934 with the help of simple dispersion 
method [6-7]. 
MATERIALS AND METHODS 
Materials 
Oxiconazole nitrate was procured from Yarrow Chem Products, 
Mumbai. Eudragit S-100, Eudragit L-100 was obtained from 
Research-Lab Fine Chem Industries Mumbai. Carbapol-934 and 
polyvinyl Alcohol was purchased from Loba Chemie Pvt. Ltd., 
Mumbai and Cosmo chem respectively. All other reagents used were 
of analytical grade. The microsponges were prepared by the quasi-
emulsion solvent diffusion method. 
Methods 
The microsponges of respective composition, as shown in table 2, 
were designed using eudragit S-100, eudragit L-100 as a polymer, 
polyvinyl alcohol as a stabilizer. Batches were designed for a 
different drug: polymer ratios and for different concentrations of 
polyvinyl alcohol at stirring speed of 1500 rpm.  
The microsponges containing oxiconazole nitrate were prepared by 
a quasi-emulsion solvent diffusion method using eudragit S-100, 
eudragit L-100 as a polymer. To prepare the inner phase, the 
polymer is added to ethyl alcohol and the drug is added to methyl 
alcohol. Polymer solution and drug solution dissolved under 
ultrasonication at 35 °C. This solution made inner phase. The inner 
phase was poured into the PVA solution in water (external phase). 
Following 2 h stirring at 1500 rpm, the mixture is filtered to 
separate the microsponges. The microsponges are dried in an air 
heated oven at 40 °C for 12 h and weighed to determine production 
yield (PY) [8]. 
 
Table 1: List of instruments 
S. No.   Instruments  Manufacturer  
1  Single Pan Electronic Balance  Shimadzu corp. model(ATX224)  
2  Infrared Spectrophotometer  FTIR-Shimadzu 
3  Ultrasonicator  Wensar Electronics Pvt. Ltd., Mumbai  
4  Mechanical Stirrer  Remi Equipments Ltd., Mumbai  
5  Magnetic Stirrer  Remi Equipments Ltd., Mumbai  
6  UV Spectrophotometer  Dynamica, Model: Halo DB-20. 
7  Differential Scanning Calorimeter  Mettler-Toledo DSC 821e, Switzerland  
8 Brook Field Viscometer  LVDV-E Brookfield Viscometer, Eng. Lab, USA  
9 Diffusion Cell  Fabricated Apparatus  
10. Digital Potentiometer Equiptronics Model(EQ-601) 
11. Motic Digital microscope B1 Advanced series. 
12. Hot air oven Biotechnics India. 
13. Dissolution test apparatus Electrolab (TDT)-08LUSP Type I 
 
Table 2: Composition of oxiconazole nitrate microsponges 
Ingredients  Formulation 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Oxiconazolenitrate (mg) 100 100 100 100 100 100 100 100 100 100 100 100 
Eudragit S-100(mg) 750 750 1000 1000 1250 1250 --- --- --- --- --- --- 
Eudragit L-100(mg) --- --- --- --- --- --- 750 750 1000 1000 1250 1250 
Ethanol (ml) 5 5 5 5 5 5 5 5 5 5 5 5 
Methanol (ml) 5 5 5 5 5 5 5 5 5 5 5 5 
PVA% w/v 0.5 0.75 0.5 0.75 0.5 0.75 0.5 0.75 0.5 0.75 0.5 0.75 
Water 100 100 100 100 100 100 100 100 100 100 100 100 
 
Evaluation of oxiconazole nitrate microsponges 
Determination of production yield 
The production yield of the microsponges was determined by 
calculating accurately the initial weight of the raw materials and the 
final weight of the microsponges obtained. 
% production yield
=
Practical mass of Microsponge 
Theorotical mass(polymer + Drug)
X100 … . Eqn(1)  
Actual drug content and encapsulation efficiency 
A sample of dried microsponges equivalent to 10 mg was taken into 
mortar and pestle and add little amount of phosphate buffer of pH 
7.4 and allowed to stand for 24 h. Then transfer content into 100 ml 
volumetric flask and make up volume to 100 ml with phosphate 
buffer of pH 7.4. The solution was filtered through Whatman filter 
paper (No.41). From the resulting solution take 1 ml into 10 ml 
volumetric flask and then make up volume to 10 ml with phosphate 
buffer of pH 7.4. Drug content was determined by UV spectro-
photometer (Dynamica, Halo DB-20) at 261 nm.  
The drug content and encapsulation efficiency were calculated using 
the following formula.  
% Encapsulation Efficiency 
=  
Actual drug content 
in Microsponge 
Theorotical drug content
X100. … Eqn(2)  
%Actual drug content =
Nact 
Nms
 X100 … . Eqn(3)  
Where Nact is the actual oxiconazole nitrate content in weighed 
quantity of microsponges, Nms is the weighed quantity of powder of 
microsponges [8-10]. 
Motic digital microscopy  
For morphology and surface topography, prepared microsponges 
can be placed on a glass slide at room temperature and then the 
surface morphology of the microsponges can be studied by Motic 
Digital Microscopy (B1 advanced series). Motic Digital Microscopy of 
a fractured microsponge particle can also be taken to illustrate its 
ultrastructure.  
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The morphology of Oxiconazole nitrate microsponge was examined 
with a Motic Digital Microscopy. The samples were mounted on a 
glass slide and observed under 10X object with the magnification 
power2048 x 1536 [11]. 
Particle size analysis  
Particle size analysis of prepared microsponges was carried out by 
using Motic digital microscope particle size analyzer [B1 advanced 
series]. Microsponges were dispersed on the slide before running the 
sample in the instrument, to ensure that the light scattering signal, 
particle size was measured, which is within instrument’s sensitivity 
range [11]. 
Infrared spectroscopy  
It was determined by Fourier Transform Infrared Spectro-
photometer (FTIR-Shimadzu) using KBr pellet method. FTIR spectra 
of oxiconazole nitrate, physical mixture(s) of oxiconazole nitrate and 
eudragit S-100, eudragit L-100, carbapol 934 and microsponge 
formulation were recorded in the wavenumber range of 4000 to 400 
cm-1 [11]. 
Differential scanning calorimetry (DSC)  
Thermal analysis is an important evaluation technique to find any 
possible interaction between the drug and excipients. Such 
interaction can be identified by any change in the thermogram. 
Thermogram of oxiconazole nitrate microsponge formulation was 
obtained using DSC instrument (PerkinElmer 4000) equipped with 
an intercooler. Indium standard was used to calibrate the DSC 
temperature and enthalpy scale. The powder sample of 
microsponges was hermetically kept in the aluminium pan and 
heated at a constant rate of 10 ˚C/min, over a temperature range of 
30˚C to 300˚C under a nitrogen atmosphere of the flow rate of 20 
ml/min [11]. 
In vitro drug release study  
The dissolution profile of Microsponges can be studied by use of 
dissolution apparatus USP (Type I) with a modified basket consisted 
of 5μm stainless steel mesh. A sample equivalent to 100 mg of 
oxiconazole nitrate was taken in the basket. The speed of the 
rotation is 100 rpm and temperature of 37±0.5˚C was maintained 
throughout the experiment. The dissolution medium (900 ml) is 
phosphate buffer pH 7.4 while considering solubility of actives to 
ensure sink conditions. At fixed intervals, aliquots were withdrawn 
and replaced with fresh dissolution medium. Samples from the 
dissolution medium can be analysed by UV spectrophotometer 
(Dynamica, Halo DB-20) at 261 nm at various intervals. The 
concentration of drug released at different time intervals was 
determined by measuring absorbance [12]. 
Formulation of microsponges entrapped oxiconazole nitrate gel 
Promising microsponges (formulation prepared by Quasi emulsion 
solvent method) Formulations of microsponges F3, F9 containing 
oxiconazole nitrate equivalent to 1 % w/w was incorporated into 
the gel base composed of Carbapol 934 (35 mg), Sodium benzoate 
(50 mg), Propylene glycol (0.75 ml), Triethanolamine (quantity 
sufficient) and distilled water up to10 ml [13]. 
Evaluation of oxiconazole nitrate gel  
Visual inspection  
The prepared gel formulation of microsponges was inspected 
visually for their color, texture and appearance [11].  
pH measurement  
The pH of gel formulation was determined by using digital pH meter. 
One gram of gel was dissolved in 100 ml distilled water and stored for 
two hours. The measurement of pH of the formulation was done [14]. 
Spreadability studies  
One of the criteria for a gel to meet the ideal qualities is that it should 
possess good spreadability. It is the term expressed to denote the 
extent of the area to which gel readily spreads on application to the 
skin or affected part. The therapeutic efficacy of a formulation also 
depends upon its spreading value. Spreadability is expressed in terms 
of time in seconds taken by two slides to slip off from gel placed in 
between the slides under the direction of certain load. Lesser the time 
is taken for separation of two slides, better the spreadability.  
Spreadability was determined by glass slides and a wooden block, 
which was provided by a pulley at one end. By this method, 
spreadability was measured on the basis of Slip and Drag 
characteristics of gels. A ground glass slide was fixed on this block. 
An excess of gel (about 1 gm) of different formulations was placed 
on the ground slide. The gel was then sandwiched between this slide 
and another glass slide having the dimension of fixed ground slide. 
Excess of the gel was scrapped off from the edges. The top plate was 
then subjected to pull of 20 gms, lesser the time is taken for 
separation of two slides better the spreadability. 
Spreadability was then calculated using the following formula:  
S = M × L/T …. Eqn (4) 
Where, S = is the spreadability, M = is the weight in the pan (tied to 
the upper slide), L = is the length moved by the glass slide T = 
represents the time taken to separate the slide completely from each 
other [11, 15]. 
Viscosity measurement  
The viscosity of the different gel formulations was determined using 
a Brookfield viscometer with spindle no. 64 at 100 rpm at 
temperature 25˚C. The viscosity of the optimised formulation was 
determined as such without dilution using Brookfield Viscometer 
(Model-LVDV-E). Brookfield Viscometer consists of a cup, which is 
stationary and a spindle which is rotating. Different sized rotating 
spindles are used and immersed in the test material. For liquids with 
low viscosity, large size spindles (large diameter and surface area) 
are used while for higher viscosity liquids small spindles (small 
diameter and surface area) are used. Rotate the spindle in the 
microsponge gel till we get a constant dial reading on the display of 
the viscometer. This procedure is repeated three times for 
reproducible results [15-16]. 
Drug content  
1 gm of oxiconazole nitrate microsponge gel was accurately weighed 
and dissolved using methanol, sonicated for a period of 10-15 min 
and made up to the mark in 100 ml volumetric flask with methanol. 
From this 10 ml was pipetted out and diluted to 100 ml with 
methanol and the final dilution was made using distilled water to get 
a concentration within Beer’s range. The absorbance was measured 
by UV spectrophotometer (Dynamica, Halo DB-20) at 260 nm 
against blank gel treated in the same manner as a sample [15]. 
In vitro diffusion study  
In vitro studies of the gel were carried out across the egg membrane 
extracted by using the concentrated HCl. The receptor 
compartments were filled with phosphate buffered saline (PBS) pH 
7.4, Study was carried out using excised egg membrane. Franz 
diffusion cell with 30 ml receptor compartment and effective area 
4.52 cm² was placed on a thermostatic magnetic stirrer and the 
temperature was maintained at 37˚C throughout the study. Selected 
batches of drug microsponge gel (MGI, MGII, M. F.) were used for the 
diffusion study using diffusion cell. Aliquots, each of 1 ml volume 
were withdrawn at specific intervals and replaced by an equal 
volume of the receptor medium. The aliquots were suitably diluted 
with the receptor medium. Release studies were carried out over a 
period of 12 h at regular intervals. Samples were withdrawn and 
analyzed by UV spectrophotometer (Dynamica, Halo DB-20) at 261 
nm [11, 15]. 
In vitro drug release kinetic study  
To determine the drug release mechanism and to compare the 
release profile differences among microsponge gel formulations, the 
data obtained from the drug released amount and time were used. 
The drug release kinetics was analyzed with mathematical models 
like Zero order, First order, Higuchi matrix, Hixson crowell and 
Korsmeyer-peppas model. Several kinetic models have been 
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proposed to describe the release characteristics of a drug from the 
matrix. The three parameters were used to study the release 
mechanism i.e. release rate constant (k), correlation coefficient (R), 
and release exponent (n) and determine the best fit model for 
optimised formulation [17]. The release data was analyzed with the 
following mathematical models:  
Zero order kinetics 
Drug dissolution from pharmaceutical dosage forms that do not 
disaggregate and release the drug slowly (assuming that area does 
not change and no equilibrium conditions are obtained) can be 
presented by the following equation:  
Q = K0t …. Eqn (4) 
Where Q is the amount of drug released at time t, K0 is the zero-
order rate constant expressed in units of concentration/time and t-is 
the time in hours.  
The pharmaceutical dosage forms following this profile, release the same 
amount of drug by a unit of time. This model represents an ideal release 
profile in order to achieve the prolonged pharmacological action [17]. 
First order kinetics 
This model has also been used to describe absorption and/or 
elimination of some drugs, although it is difficult to conceptualise 
this mechanism on a theoretical basis.  
Q1 = Q0 e-K1t or 
Log Q1 =Log Q0+
K1t
2.303
 …. Eqn (5) 
Where Q1 is the amount of drug released in time t,  
Q0 is the initial amount of drug in the solution and  
K1 is the first order release constant.  
The pharmaceutical dosage form following this dissolution profile, 
such as water soluble drugs in porous matrices releases the drug in 
such a way that is proportional to the amount of drug remaining in 
its interior, in such a way that the amount of drug released by a unit 
of time diminishes [17]. 
Higuchi matrix model 
This model is used to study the release of water soluble and low 
soluble drugs incorporated in semisolid and/or solid matrices. 
Mathematical expressions were obtained for drug particles 
dispersed in a uniform matrix behaving as the diffusion media. It 
describes drug release as a diffusion process based on the Fick’s law, 
square root time dependent [17]. 
Q = KH t1/2…. Eqn (6) 
Where Q is the amount of drug release in time t,  
KH is the Higuchi dissolution constant.  
Korsmeyer-peppas model 
Korsmeyer developed a simple, empirical model, relating 
exponentially the drug release to the elapsed time (t).  
ft= a. tn…. Eqn (7) 
Where a is a constant incorporating structural and geometric 
characteristics of the drug dosage form, n is the release exponent, 
indicative of the drug release mechanism and function of t is Mt/M∞ 
(fractional release of drug) [17]. 
Hixson-Crowell model 
Hixson and Crowell (1931) recognised that the particles regular area 
is proportional to the cube root of its volume. They derived the 
equation:  
W0 1/3-Wt 1/3= κ t …. Eqn (8) 
Where W0 is the initial amount of drug in the pharmaceutical dosage 
form, Wt is the remaining amount of drug in the pharmaceutical 
dosage form at time t and κ (kappa) is a constant incorporating the 
surface volume relation. The equation describes the release from 
systems where there is a change in surface area and diameter of 
particles or tablets. To study the release kinetics, data obtained from 
in vitro drug release studies were plotted as the cube root of drug 
percentage remaining in matrix versus time [17]. 
RESULTS AND DISCUSSION 
Determination of production yield and encapsulation efficiency 
The production yield of all batches was ranged from 61.44% to 
80.45%. It was found that production yield was greatly affected by 
drug: polymer ratio as well as by concentration of polyvinyl alcohol. 
It was indicated that increasing polymer concentration, increased 
production yield while increasing polyvinyl alcohol concentration, 
decreased production yield. 
Use of the higher amounts of PVA while preparing microsponges at a 
higher drug: polymer ratios caused slightly an increased viscosity of 
the dispersed phase. When solvents in inner phase were diffused 
out, nearly all of the dispersed phase was converted to the form of 
solid microsponges and separated particles appeared. The highest 
drug loading efficiency of these formulations could be explained 
through the fact that the amount of polymer to per unit drug was 
greater than that in other formulations. 
 
Table 3: Evaluation of oxiconazole nitrate microsponges 
Batches Production yield (%) Actual drug content (%) Encapsulation efficiency (%) 
F1 63.53±0.01 60.21 60.21 
F2 61.44±0.02 54.23 54.23 
F3 77.81±0.01 79.25 79.25 
F4 73.84±0.02 75.29 75.29 
F5 80.45±0.03 80.12 80.12 
F6 78.51±0.01 78.36 78.36 
F7 64.47±0.01 58.24 58.24 
F8 63.80±0.02 53.48 53.48 
F9 76.81±0.01 77.80 77.80 
F10 75.93±0.01 75.24 75.24 
F11 79.86±0.01 79.14 79.14 
F12 78.81±0.01 76.53 76.53 
(mean±SD; n=3) 
 
Motic digital microscopy 
The morphology of the microsponges prepared by quasi-emulsion 
solvent diffusion method and entrapment method was investigated 
by Motic Digital microscope (B1 Advanced series). The 
representative motic microscopic image of the microsponges are 
shown in fig. 1a. The image showed the microsponges to be porous 
and was having predominantly spherical shape and not much entire. 
 Oxiconazole nitrate crystals were observed visually. 
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The pores were induced by the diffusion of the solvent from 
the surface of the microsponges. The appearance of the 
particles was such that they were termed as microsponges. 
From fig. 1a it was revealed that the characteristic internal 
structure was a spherical cavity enclosed by a rigid shell 
constructed from drug and polymer. The inner structure 
consisted of void spaces. From fig., 1b microsponge gel image 
by Motic Digital microscope (B1 Advanced series) showed that 
microsponge are entrapped uniformly in three-dimensional 
cross-linked networks within the liquid. 
 
 
Fig. 1a): Image of oxiconazole nitrate microsponges 
Particle size analysis 
The mean particle size of microsponge formulations should be in the 
range of 5-300 um. The F3 and F9 batch possessed more percent of 
intact, uniform, spherical particles in optical microscopy; so this 
batches was chosen for further analysis using Motic Digital 
Microscope (B1 Advanced series). The F3 and F9 batch results 
revealed particle size corresponding to 59.7 µmand 70.7 µm. 
 
 
Fig. 1b): Image of oxiconazole nitrate microsponge gel 
 
In vitro drug release study 
The cumulative percent drug release (% CDR) for all formulations 
was calculated out. The cumulative percent drug release of all 
formulations was as quoted in table 4 and 5. 
 
Table 4: In vitro drug release profile of F1-F6 
Time (h) Formulations (% CDR) 
 F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 
1 1.76 1.30 4.44 2.84 1.85 1.32 
2 4.22 5.86 12.71 9.79 7.40 6.18 
3 13.15 11.10 20.55 10.80 15.26 14.04 
4 17.70 15.63 26.64 15.36 18.50 19.95 
5 29.16 22.02 37.56 28.77 23.74 32.05 
6 36.53 33.95 43.57 40.15 36.19 41.50 
7 48.72 40.52 62.81 53.31 58.23 57.55 
8 65.68 54.58 87.77 75.65 70.66 67.71 
 
Table 5: In vitro drug release profile of F7-F12 
Time (h) Formulations (% CDR) 
 F7 F8 F9 F10 F11 F12 
0 0 0 0 0 0 0 
1 2.13 1.94 3.45 1.85 4.72 5.14 
2 9.44 8.33 8.22 9.44 12.09 8.19 
3 18.50 15.33 15.63 18.50 23.24 15.99 
4 21.92 18.13 28.09 19.80 31.07 23.15 
5 29.60 24.70 45.72 25.44 38.05 32.28 
6 35.52 32.56 68.81 37.65 42.12 44.19 
7 49.03 49.58 78.53 54.76 54.66 52.33 
8 62.62 59.57 83.24 68.64 70.14 68.62 
  
The drug release was found to be decreased in the range of 87.77 % 
to 54.58 % for eudragit S-100 as the drug: polymer ratio was 
changed. The drug release was found to be decreased in the range of 
83.24 % to 59.57 % for eudragit L-100 as the drug: polymer ratio 
was changed. The reason behind is a drug: polymer ratio was 
increased, the amount of polymer available per microsponge to 
encapsulate the drug becomes more, thus increasing the thickness of 
the polymer matrix wall which might lead to longer diffusion path 
and ultimately to decreased drug release. The highest drug release 
i.e. 87.77 % was found for the formulation F3, while the lowest 54.58 
% for F2 for eudragit S-100. The highest drug release i.e. 83.24 % 
was found for the formulation F9, while the lowest 59.57 % for F8 
for eudragit L-100. It has been reported that with increasing amount 
of PVA from batches F1-F12, the drug release went on decreasing. It 
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might be due to fact that the polymer matrix releases drug after 
complete swelling and time required for swelling of the polymer is 
directly proportional to stabilizer concentration. Batch F3 and F9 
showed 87.77% and 83.24% drug release in 8 h. Thus they were 
further formulated as gel formulation as MGI and MGII. 
Drug-excipient interaction study by FTIR spectrum:  
FTIR spectroscopic study revealed that there was no appearance of 
any new peak and disappearance of existing peaks, which indicated 
that there was no chemical interaction between the drug and 
polymer used. The IR spectrum exhibited distinctive peaks at 
1479.40 (cm-1) due to C=N stretching. The peaks at 1712.35 (cm-1) is 
due to the C=C stretching and at 752.24 (cm-1) is due to the C-Cl 
stretching. The peak at 2951.09 is due to the C-H methylene 
stretching. The peak at 1384.89 is due to N-O stretching. All the 
characteristic peaks of oxiconazole nitrate were observed in the IR 
spectra of physical mixture and oxiconazole nitrate loaded 
microsponges during the investigation of compatibility study. 
Hence IR spectroscopy results showed that the drug was compatible 
with selected polymer and excipients. This suggested that 
oxiconazole nitrate was compatible with selected polymers and it 
was apparently stable in the microsponges. 
 
 
Fig. 2: FTIR spectrum of oxiconazole nitrate 
 
 
Fig. 3: FTIR spectrum of optimized formulation 
 
Drug-excipient interaction study by DSC thermogram 
In DSC studies, dispersed in polymer showed the same thermal 
behaviour as a pure compound. In the thermogram, the endothermic 
peak was observed at 106.31 °C which does not correspond to the 
melting point of the pure drug. During formulation of microsponges, 
the drug was entrapped inside the microsponges and was not 
available for showing any exothermic peak. Hence, no endothermic 
peak near to the melting point of the drug was observed confirming 
the entrapment of drug in microsponges. This indicates that the 
physical properties of oxiconazole nitrate are altered during 
formulation of microsponges using eudragit S-100. 
 
 
Fig. 4: DSC thermogram of oxiconazole nitrate 
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Fig. 5: DSC thermogram of optimized formulation 
 
Oxiconazole nitrate microsponge gel 
Evaluation of oxiconazole nitrate microsponge gel 
Visual inspection 
The prepared gel formulations of oxiconazole nitrate microsponges 
were inspected visually for their color, texture and appearance. All 
prepared formulations were pearl white, viscous preparations with 
a smooth texture and showed good homogeneity with the absence of 
any lumps and syneresis. 
pH measurement 
The pH value of all prepared formulations was found to be in the 
range of 6.7 to 6.8, which was considered to be acceptable to avoid 
the risk of irritation upon application to the skin. 
 
Table 6: Evaluation of oxiconazole nitrate microsponge gel 
Formulation PH Spreadability (g. cm/sec) Viscosity (cps) Drug content (%) 
MGI 6.8±0.06 7.5±0.33 1000±2 87.59±0.03 
MGII 6.7±0.06 5.0±0.25 1010±2 81.79±0.01 
Marketed formulation 6.8±0.06 6.0±0.17 1025±0.58 96.91±0.01 
 (mean±SD; n=3) 
 
Spreadability study 
The values of spreadability indicated that the gel was easily 
spreadable by a small amount of shear. Spreadability of microsponge 
gel (MGI) was found to be 7.5g. Cm/sec; indicating that spreadability 
of drug loaded microsponge gel was good. 
Viscosity studies 
The viscosities studies for microsponge formulations were carried 
out. The viscosities of all formulations are shown in Table 6. From 
above result, microsponge gel (MGI) has required viscosity. 
Drug content studies 
Drug content studies for microsponge formulations were carried 
out. Drug content of all formulations are shown in table 6. The drug 
content of the formulations showed that the drug was uniformly 
distributed in the gels. From above result, microsponge gel (MGI) 
has higher drug content. 
In vitro diffusion study 
The in vitro diffusion studies were carried out for all formulations 
using PBS (pH 7.4). In vitro diffusion of formulation MGI, MGII, M. F. 
is shown in table 7. 
 
Table 7: Amount of drug diffused per unit area of microsponge gel formulations 
Time (h) Formulations (%CADD/cm2) 
 MGI MGII Marketed formulation 
0 0 0 0 
1 10.41 0.95 2.98 
2 15.64 5.73 12.65 
6 19.30 11.42 27.87 
4 28.82 21.06 47.22 
5 37.92 30.42 71.17 
6 46.74 39.65 80.12 
7 56.31 48.99 95.98 
8 64.83 67.99 ----- 
9 70.21 82.53 ----- 
10 76.64 93.53 ----- 
11 81.82 ------ ----- 
12 92.40 ------ ----- 
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It was observed that the formulation F3 (MGI) showed a higher 
amount of drug diffused at the end of 12 h while that of F9 (MGII) and 
Marketed Formulation showed the higher amount of drug diffused at 
the end of 10 h and 7 h respectively. The results indicated that the Q 
value (cumulative amount of drug permeated per unit skin surface 
area) was controlled for 12 h at MGI drug: polymer ratio and at 0.5% 
w/v PVA. The cumulative amount of drug permeated per unit skin 
surface area (Q) from the microsponge loaded gel formulation MGI 
was 92.40%. Hence, the microsponge loaded gel formulation MGI was 
optimized formulation and drug release kinetic study was done. 
Drug release kinetic study of optimized formulation MGI (F3) 
To determine the kinetics of release, drug diffusion data were 
treated with different kinetic equations. Obtained drug diffusion 
data was fitted to Zero order, First order, Higuchi matrix model, 
Hixson crowell model and Korsmeyer-peppas model. The three 
parameters were used to study the release mechanism i.e. release 
rate constant (k), correlation coefficient (R), release exponent (n). 
Correlation coefficient (R), release rate constant (k), of optimized 
formulation F3 (MGI), is reported in table 8. 
 
Table 8: Release kinetics of optimized formulation (F3) MGI 
Model Formulation code 
Zero order k 0.1171 
R 0.9969 
First order k -0.0020 
R 0.9666 
Higuchi matrix k 2.5742 
R 0.9321 
Hixson crowell k -0.0005 
R 0.9860 
Korsmeyer peppas k 0.1983 
R 0.9905 
 n 0.9134 
Best fit model Zero order model 
 
The model that fits the release data was selected based on the 
correlation coefficient (R) value in various models. The model that 
gave the high ‘R’ value was considered as the best fit of release data. 
Korsmeyer peppas model best described the sustained release of 
optimized F3 (MGI) formulation and the diffusion exponent (n) 
value was found to be 0.9134 suggesting that the Ficks law of 
diffusion was not followed. From the result, the best fit model for 
optimised formulation F3 (MGI) is Zero order. 
CONCLUSION 
The gel containing microsponges showed the viscous modulus. This 
study concluded that microsponges prepared with eudragit S-100 and 
eudragit L-100 in the 1:10 (F3) were more efficient to give extended 
drug release which released the 87.77% and 83.24% drug at the end of 
8 h. Microsponge formulation F3 and F9 showed good physical 
parameter study and was used for formulating into gel, incorporated 
in the carbapol. The microsponge gel prepared with eudragit S-100 in 
the batch MGI (F3) was showed good physical parameters and more 
efficient to give extended drug release which released the 92.40 % 
drug at the end of 12 h. The optimised formulation MGI (F3) followed 
Zero order kinetics and non-fiction diffusion. As compared to 
conventional formulation, these microsponge gel are expected to 
remain on the skin for a longer time, gradually releasing their contents 
over the time. Hence, oxiconazole nitrate microsponges and 
microsponge gel prepared in this study are promising as being more 
useful than conventional formulation therapy. 
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